He recently disclosed on social media that he discontinued the use of rapamycin on September 28, ending a five-year ...

The US Food and Drug Administration has not approved rapamycin for anti-aging therapy, but physicians have been prescribing it off-label because it has been shown to extend the healthy lifespan of ...

There isn’t much research supporting any one supplement in terms of its benefits for longevity—except for potentially vitamin ...

Now, that dream may be inching closer to reality. Researchers are developing an anti-aging drug for dogs, and trials are showing promising results. But could the science behind this drug hold the ...

Recently, researchers at the University of Liverpool found that rilmenidine, a common medication used to treat high blood ...

This capability is crucial for understanding aging-related pathways ... novel targets for anti-ageing, and age-related diseases. For instance, Insilico’s leading drug candidate INS018_055 ...

A Midtown-based therapeutics company hopes to tap the growing market of anti-aging drugs with a suite of pharmaceutical research, and investors are taking notice. Cambrian Bio recently raised $23 ...

Researchers have developed AI-driven evaluation standards to enhance ageing-related interventions, aiming to improve health ...

The best newsA new anti-aging drug for dogs is expected to be available to buy by next year.The groundbreaking ...

Bryan Johnson, the 47-year-old tech entrepreneur known for his extensive anti-aging efforts, has stopped using Rapamycin, a ...

More information: Bowen Tang, Investigating drug effects on aging and alzheimer's disease using causal inference approaches, (2025). DOI: 10.69622/27889941.v1 Provided by Karolinska Institutet ...

The drug, known as LOY-002 ... Although it is not approved for use as an anti-aging treatment in humans, many gerontologists see rapamycin as the best hope for pharmacologically slowing the ...